Patents Assigned to MethylGene Inc.
-
Patent number: 7253204Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: March 25, 2005Date of Patent: August 7, 2007Assignee: MethylGene Inc.Inventors: Daniel Delorme, Arkadii Vaisburg, Oscar Moradei, Silvana Leit, Stephane Raeppel, Sylvie Frechette, Giliane Bouchain, Zhihong Zhou, Isabelle Paquin, Frederic Gaudette, Ljubomir Isakovic
-
Publication number: 20070155730Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein A, B, D, E, X1, X2, X3, X4 and n are as defined in the specification.Type: ApplicationFiled: August 25, 2006Publication date: July 5, 2007Applicant: METHYLGENE, INC.Inventors: Silvana Leit, Amal Wahhab, Martin Allan, David Smil, Pierre Tessier, Robert Deziel, Yves Chantigny
-
Publication number: 20070105808Abstract: The invention relates to the inhibition of histone deacetylase expression and enzymatic activity and, in particular, to the inhibition of a specific histone deacetylase. The invention also relates to compositions comprising antisense oligonucleotides and methods of using the same to inhibit a histone deacetylase. Also disclosed are methods for identifying a histone deacetylase involved in induction of cell proliferation, and methods for identifying compounds that interact with and reduce the enzymatic activity of such a histone deacetylase.Type: ApplicationFiled: November 9, 2006Publication date: May 10, 2007Applicant: MethylGene, Inc.Inventors: A. MacLeod, Zuomei Li, Jeffrey Besterman
-
Patent number: 7205285Abstract: The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not possess a ?-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as ?-lactamase inhibitors and as antibiotics.Type: GrantFiled: July 28, 2003Date of Patent: April 17, 2007Assignee: Methylgene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Rex Pratt
-
Publication number: 20060105999Abstract: The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: ApplicationFiled: November 19, 2003Publication date: May 18, 2006Applicant: MethylGene, Inc.Inventors: Jeffrey Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Patent number: 7030103Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: October 8, 2002Date of Patent: April 18, 2006Assignee: Methylgene, Inc.Inventors: Jeffrey M. Besterman, Daniel Delorme, Jubrail Rahil
-
Publication number: 20060074056Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.Type: ApplicationFiled: July 28, 2005Publication date: April 6, 2006Applicant: MethylGene, Inc.Inventors: Arkadii Vaisburg, Stephen Claridge, Franck Raeppel, Oscar Saavedra, Naomy Berstein, Marie-Claude Granger, Lijie Zhan, Amal Wahhab, David Llewellyn
-
Publication number: 20060020131Abstract: The invention provides compoods and methods for treating cell proliferative-diseases. The invention provides new inhibitors of histone deacetylase enzymatic activity, compositions of the compounds comprising the inhibitors and a pharmaceutically acceptable carrier, excipient, or diluent, and methods of using the compounds to inhibit cellular proliferation in vitro and therapeutically.Type: ApplicationFiled: October 16, 2003Publication date: January 26, 2006Applicant: Methylgene, Inc.Inventors: Stephane Raeppel, Frederic Gaudette, Isabelle Paquin, Arkadii Vaisburg, Daniel Delorme
-
Patent number: 6953783Abstract: The invention relates to the modulation of gene expression. In particular, the invention relates to compositions comprising antisense oligonucleotides which inhibit expression of a gene in operable association with protein effectors of a product of that gene, and methods of using the same. In addition, the invention relates to the modulation of mammalian gene expression regulated by methylation.Type: GrantFiled: October 19, 1999Date of Patent: October 11, 2005Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Robert A. Macleod, William M. Siders, Zuomei Li
-
Patent number: 6921756Abstract: The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: April 8, 2003Date of Patent: July 26, 2005Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Patent number: 6897220Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: February 4, 2003Date of Patent: May 24, 2005Assignee: MethylGene, Inc.Inventors: Daniel Delorme, Zhihong Zhou
-
Patent number: 6884791Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: November 22, 2002Date of Patent: April 26, 2005Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Publication number: 20050043276Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: ApplicationFiled: July 2, 2004Publication date: February 24, 2005Applicant: MethylGene, Inc.Inventors: Jeffrey Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Publication number: 20040142953Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: ApplicationFiled: February 4, 2003Publication date: July 22, 2004Applicant: MethylGene, Inc.Inventors: Daniel Delorme, Zhihong Zhou
-
Publication number: 20040082546Abstract: The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: ApplicationFiled: April 8, 2003Publication date: April 29, 2004Applicant: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Patent number: 6608046Abstract: The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not possess &bgr;-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as &bgr;-lactamase inhibitors and as antibiotics.Type: GrantFiled: September 1, 2000Date of Patent: August 19, 2003Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Rex Pratt
-
Patent number: 6541661Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: November 22, 2000Date of Patent: April 1, 2003Assignee: MethylGene, Inc.Inventors: Daniel Delorme, Rejean Ruel, Rico Lavoie, Carl Thibault, Elie Abou-Khalil
-
Patent number: 6472406Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: July 5, 2000Date of Patent: October 29, 2002Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Daniel Delorme, Jubrail Rahil
-
Patent number: 6268137Abstract: The invention provides novel mechanism-based inhibitors of DNA methyltransferase enzyme, and diagnostic and therapeutic uses for the same. The novel inhibitors according to the invention form stable, noncovalent complexes with DNA methyltransferase enzyme in a manner which is independent of S-adenosylmethionine.Type: GrantFiled: December 8, 1998Date of Patent: July 31, 2001Assignee: Methylgene, Inc.Inventors: Moshe Szyf, Pascal Bigey
-
Patent number: 6221849Abstract: The invention provides recombinant nucleic acids comprising nucleic acid sequences from the genomic DNA methyltransferase gene. The invention further provides sequence information for such nucleic acid sequences. In addition, the invention provides antisense oligonucleotides complementary to special regions of the genomic DNA methyltransferase gene or its RNA transcript. Finally, the invention provides methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic plant and animal studies and gene therapy approaches, and as potential therapeutic agents.Type: GrantFiled: June 24, 1998Date of Patent: April 24, 2001Assignee: MethylGene, Inc.Inventors: Moshe Szyf, Pascal Bigey, Shyam Ramchandani